Under the inspiring theme “Invest in Health,” the event brings together experts, innovators, and thought leaders from more than 130 countries to share ideas and showcase cutting-edge advancements shaping the medical world.

The Makkah Health Cluster’s participation is a reflection of Saudi Arabia’s commitment to healthcare transformation in alignment with Vision 2030.

This national vision emphasizes the modernization of healthcare systems, integration of advanced technologies, and creation of a sustainable health infrastructure that benefits citizens and residents alike.

The cluster’s innovative use of artificial intelligence stands as a powerful example of how smart technologies are making healthcare faster, more efficient, and more patient-centered.

One of the cluster’s most celebrated innovations at the exhibition is the iSelfie project, a revolutionary AI-based health assessment tool that utilizes photoplethysmography (PPG) technology.

This innovative approach allows for the rapid evaluation of a patient’s vital signs by simply analyzing facial features through a camera, making the process non-invasive, accurate, and highly efficient.

Traditionally, emergency departments required an average of seven minutes per patient assessment; however, with iSelfie, that time has been cut down to just two minutes.

This represents a 70 percent reduction in time, dramatically improving emergency department efficiency and patient flow.

The cluster’s efforts are not only focused on innovation but also on cost-efficiency and sustainability. Through the introduction of its smart vital signs project, Makkah Health Cluster plans to implement AI-powered solutions across 14 hospitals and 15 primary healthcare centers.

This initiative is expected to save SR120,000 ($32,000) annually by replacing traditional Dynamap devices with automated digital tools.

Beyond the financial savings, the initiative aims to enhance workflow management, allowing healthcare professionals to spend more time providing direct patient care instead of manual data collection and monitoring.

Moreover, this transformation has a significant impact on workforce optimization. By incorporating AI automation, the project is projected to reduce nursing costs by SR15.3 million annually and enhance operational efficiency by up to 50 percent, all while maintaining high-quality healthcare standards.

These advancements reflect how digital transformation is empowering healthcare institutions to deliver better outcomes with fewer resources, making healthcare more sustainable in the long run.

The integration of AI within healthcare is one of the core priorities of Vision 2030, which envisions a digitally advanced, patient-driven health system.

The innovations presented by Makkah Health Cluster directly support this mission by improving accessibility, enhancing diagnostic accuracy, and promoting self-care through technology.

These projects are reshaping how healthcare is delivered in Saudi Arabia—making it more proactive, predictive, and personalized.

The Global Health Exhibition serves as an essential platform for global collaboration, featuring over 100 dialogue sessions and workshops dedicated to the future of healthcare.

Topics range from artificial intelligence and biotechnology to health investments and sustainable medical practices.

Experts and participants from around the world are engaging in meaningful discussions about how AI can redefine patient care, streamline hospital management, and address pressing healthcare challenges across different regions.

Makkah Health Cluster’s participation highlights the Kingdom’s growing influence in global health innovation.

By sharing its pioneering projects and success stories, the cluster demonstrates how Saudi healthcare institutions are becoming models of excellence, blending innovation with compassion.

These initiatives underscore a collective vision—one that looks beyond traditional healthcare systems toward a smarter, healthier, and more connected future.

Ultimately, the Makkah Health Cluster’s showcase at the Riyadh expo reflects not only technological progress but also a deep commitment to improving lives.

Through AI-driven innovation, efficiency gains, and dedication to patient-centered care, the cluster is helping Saudi Arabia position itself as a global leader in digital health transformation, paving the way for a new era of accessible, intelligent, and sustainable healthcare solutions for all.

The initiative, which includes targeted adjustments at its Clayton, North Carolina facility, reflects the company’s ongoing efforts to enhance operational efficiency and future-proof production of its world-renowned health products.

While some workforce adjustments have occurred at the Clayton site, the plant remains a vital hub for manufacturing Novo Nordisk’s groundbreaking obesity and diabetes treatments, including Wegovy and Ozempic.

The changes primarily affect front-line technical and production roles, but the facility continues to play a crucial role in producing semaglutide, the active ingredient powering these revolutionary therapies. Novo Nordisk has emphasized that supporting affected employees during this transition is a top priority.

The company’s restructuring strategy comes as part of its plan to adapt to evolving global healthcare demands, streamline production, and strengthen cost efficiency. By realigning operations, Novo Nordisk aims to focus more resources on research, innovation, and sustainable expansion, particularly in the U.S., its fastest-growing market.

This strategic move underscores its commitment to quality, patient access, and continuous improvement in the face of intensifying global competition.

Despite the operational adjustments, Novo Nordisk’s outlook remains strong and optimistic. The company has reaffirmed its long-term plans to expand U.S. production capacity and advance the next generation of treatments, including the upcoming oral version of Wegovy, which will be partly manufactured at the Clayton plant.

This development highlights the company’s focus on innovation and accessibility, offering patients more convenient and effective options for managing obesity and diabetes.

The restructuring follows a period of rapid growth that saw Novo Nordisk become Europe’s most valuable company, driven by unprecedented demand for its weight-loss and metabolic health products.

After years of expansion, the company is now optimizing its structure to sustain momentum and build resilience, ensuring resources are efficiently directed toward future breakthroughs and global health goals.

A Novo Nordisk spokesperson expressed that the process of restructuring is being handled thoughtfully and responsibly, prioritizing employee welfare and transparent communication.

“This process takes time, and our highest priority is to support our employees,” the company stated, reflecting its enduring values of care, respect, and accountability that define its corporate culture.

Market observers view Novo Nordisk’s restructuring as a positive, forward-looking measure, positioning the company to strengthen its leadership in the competitive healthcare landscape.

The streamlining efforts are expected to boost productivity and accelerate innovation, enabling the firm to continue delivering life-changing treatments to millions of patients around the world.

While approximately 9,000 roles are being restructured globally, these changes represent a strategic optimization rather than a contraction.

The company continues to invest heavily in advanced manufacturing technologies, sustainable production, and digital transformation — all of which are essential to maintaining its leadership in diabetes and obesity care.

The Clayton facility, one of Novo Nordisk’s largest and most advanced sites, remains integral to its U.S. growth strategy. It supports key production processes, including the filling, finishing, and packaging of injectable medications.

The site is also expected to contribute significantly to new product development and innovation, ensuring a robust supply chain for current and future therapies.

By proactively reshaping its workforce and resources, Novo Nordisk is reinforcing its position as a global leader in healthcare innovation.

The restructuring demonstrates the company’s ability to evolve with market conditions, maintain high standards, and prepare for the next wave of scientific and technological advancement.

As Novo Nordisk continues this strategic transition, industry experts anticipate stronger performance, renewed agility, and sustainable global growth.

The company’s commitment to patients, employees, and long-term value creation remains unwavering — signaling confidence in its mission to improve lives through medical innovation.